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Background/aim: Enteral feeding and immunonutrition (ImN) have been shown to be associated with a number of favorable effects in
patients undergoing cancer surgery. In this prospective study, we aimed to assess the perioperative use of enteral immunonutrition in
patients undergoing radical gastrointestinal surgery for malignancy.
Materials and methods: Forty-one patients with malignancy were included in this study and were randomized into one of the two
following nutritional strategies: enteral only (EN) or enteral with enteral immunonutrition (ENIN). These regimens were followed for
7 days perioperatively by all patients. Nutritional parameters and postoperative morbidity, mortality, and length of hospital stay (LHS)
were assessed.
Results: Serum prealbumin levels increased significantly in the ENIN group (P = 0.033). Moreover, patients in the ENIN group showed
a more marked decrease in the rate of postoperative infections (P = 0.021) and anastomotic leakage (P = 0.018) than patients fed with
EN. In the EN group, LHS was significantly longer than that in the ENIN group (18 vs. 12 days) (P = 0.032). Rates of overall morbidity
and mortality were similar in the two groups (P > 0.05).
Conclusion: ENIN was found to have a favorable effect on the outcome of radical gastrointestinal surgery for malignancy. Meticulous
preoperative assessment of malnutrition and at least a 7-day perioperative enteral use can increase the effectiveness of immunonutrition.
Key words: Immunonutrition, enteral, gastrointestinal surgery, cancer

1. Introduction
Energy and protein depletion with consequent
malnutrition is a common occurrence in patients with
gastrointestinal cancers (1,2) and represents a major cause
of morbidity, mortality, and decreased survival (3).
During the course of malignancies, more than 50% of
the patients experience significant weight loss. Depletion
of body stores in conjunction with dysfunctional protein
synthesis and immune response result in the impairment
of wound healing and body resistance against infections
(4,5), increasing the risk of postoperative complications
and prolonged hospital stay in this group of patients (6).
Replacement of the body stores after an initial assessment
of malnutrition status and cachexia caused by cancer has
recently become a more popular perioperative nutritional
strategy (7). Nutritional therapy is carried out either by
parenteral nutrition (Pn) or enteral feeding (Ef), and the
latter is generally more frequently preferred by surgeons
owing to certain advantages over Pn, including being safer
* Correspondence: synumunelicerrah@gmail.com

and having more physiological and economic benefits
(8,9).
Immunonutrition (ImN) consists of arginine
supplementation combined with glutamine, a leucine
metabolite hydroxy-methyl-butyrate (HMB), omega-3
fatty acids, and ribonucleic acid. These immunonutrients,
in addition to protein turnover modulation, enhance
wound healing and immune functions (10–12), resulting
in decreased rates of surgical site infections, other
infectious complications, and shortened hospital stay
after gastrointestinal cancer surgery (13,14). Previous
studies on ImN have examined several of its aspects such
as the timing (pre-/postoperative or both), the route
of replacement (parenteral/enteral), benefits, and the
decisive threshold of malnutrition following which such
nutritional strategies are beneficial (15–17).
Previous studies have already looked at the role of ImN
in different types of gastrointestinal malignancies. The
aim of this prospective study was to evaluate the effects
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of perioperative use of enteral ImN (ENIN) in upper
gastrointestinal cancer surgery involving malignancies
above the Treitz’s ligament.
2. Materials and methods
This prospective, randomized study was undertaken at the
Department of Surgery, Derince Training and Research
Hospital, Kocaeli, Turkey, between January 2012 and
February 2013. Forty-one patients with malignancies of
the upper gastrointestinal tract were included. The study
protocol was approved by the local ethics committee
and informed consent was obtained from all patients.
The purpose of the study was to evaluate the effect of
perioperative ENIN on morbidity (overall and specific
incidence of complications), mortality, and length of
hospital stay (LHS) after elective radical gastrointestinal
surgery. The following two nutritional strategy groups
were defined: enteral only (EN) and ENIN. While both
groups of patients were provided with enteral nutrition
perioperatively, patients in the ENIN group also received
additional ImN. Following nutritional status assessment,
patients were randomly assigned into one of the two
nutrition groups. The nutritional team that organized the
two nutrition regimes was blind to the groups.
2.1. Patients, inclusion criteria
Malignancies for study inclusion included cancers of the
distal esophagus, stomach, and head of the pancreas.
Exclusion criteria included stage 4 malignancies; coexistent
severe lung, kidney, heart, or liver diseases; age less than
18 or greater than 75 years; and nutritional therapy
intolerance. Nutritional status and malnutrition severity
were evaluated using patient history, subjective global
assessment (SGA), and laboratory tests. The body mass
index (BMI) was also estimated preoperatively. Nutritional
support was carried out in patients with unintentional
weight loss exceeding 10% of their bodyweight and in
those with a SGA group of B or C. Laboratory tests to
evaluate the nutritional status in each patient included
plasma albumin, prealbumin, and transferrin. In addition,
the complete blood count (CBC) and biochemical markers
of organ functions (plasma urea, creatinine, aspartate and
alanine amino transferase, bilirubin, sodium, potassium,
calcium, etc.) were analyzed.
2.2. Surgical interventions
Several procedures such as distal esophagectomy, total or
subtotal gastrectomy, or pancreaticoduodenectomy were
implemented according to the malignancy. In patients
with gastric cancer, standard D2 lymph node dissection
was also performed. For antibiotic prophylaxis cefazolin
sodium 1 g i.v. was given 30 min prior to surgery. Repeated
doses were administered if surgery time exceeded 4 h.
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2.3. Nutritional support and assessment
Nutritional support was provided for 7 days before and 7
days after the intervention. Although oral route was the
initial choice of nutrition preoperatively, tube feeding
was also used in patients with insufficient oral intake.
While enteral nutrition was accomplished with Ensure
Plus (Abbott Nutrition) in both groups, Abound (Abbott
Nutrition) was used in the ENIN patients for ImN. The list
of ingredients found in these nutritional products is given
in Table 1. Immunonutrient protocol, i.e. Abound, was
administered 2 times a day in 250 mL of watery solution.
Adequate amounts of two main immunonutrients,
glutamine (>14 g/day) and arginine (>12 g/day), were
provided in the ENIN group.
Patients’ energy requirements were calculated
using the Harris–Benedict formula. Postoperative
energy replacement did not exceed 30 kcal/kg per day.
Postoperative protein requirement was set at 2 g per kg
of body weight. Following surgery, nutritional protocols
were initiated after 24 h using nasoenteral or feeding
jejunostomy tubes. Postoperatively, EN was given at a dose
of 30 mL/h on day 1, followed by 50 mL/h on day 2, and
the target dose was reached on postoperative day 3. All
patients received EN or ENIN for a minimum duration of
7 days postoperatively. Nutritional support was continued
in patients who had ineffective/inadequate oral intake at
hospital discharge. On preoperative day 1, postoperative
day 6, and postoperative day 8 total blood counts and
biochemical assays were performed.
2.4. Investigational parameters
The purpose of the present study was to investigate the
effects of perioperative use of ImN on postoperative
morbidity, mortality, and LHS. Mortality was defined as
death occurring within 30 days after hospitalization. LHS
was defined as the duration of time from the day of surgery
until the day of discharge. Other variables such as duration
Table 1. Ingredients of the feeding solutions.
Nutrients

Abound*

Ensure Plus**

Proteins (g)

14.8

15.6

L-arginine

7.4

-

L-glutamine

7.4

-

HMB

1.3

-

Carbohydrates (g)

7.8

50.5

Lipids (g)

0.02

12.3

Energy (kcal)

91

375

*each 24-g sachet.
**per 250 mL.
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of operation, requirement for blood transfusions, and
nutritional parameters were recorded.
2.5. Statistical analysis
All data were collected and analyzed using SPSS 16.0 (SPSS
Inc., Chicago, IL, USA). Within-group differences were
analyzed using the paired t test and differences between
groups were analyzed using the Mann–Whitney U test and
chi-square test, where applicable. P < 0.05 was considered
significant.
3. Results
In a 13-month period, 41 patients (22 male, 19 female)
were included in the study. Various baseline parameters
(such as the demographic characteristics of the patients)
are shown in Table 2. There were no significant differences
between the two groups in terms of age, sex, nutritional
parameters, or surgical characteristics.
Nutritional status was evaluated by perioperative
assessment of plasma albumin, prealbumin, and transferrin
(Table 3). Although an increasing trend was observed in
all of these parameters in both groups, only the change in
prealbumin in group ENIN reached statistical significance

(P = 0.033). The percent increase in transferrin levels
was higher as compared with plasma albumin in patients
with ImN, although the difference was not significant (P
= 0.125). EN did not appear to have a favorable impact
on these variables. Infectious complications occurred
at a significantly lower frequency in the ENIN patients
than in the EN patients (11.7% vs. 31.3%, P = 0.021). In
addition, a positive effect of ImN on LHS was observed,
with significantly shorter postoperative LHS in the
ENIN group than in the EN group (12 vs. 18 days, P =
0.032). In our study, morbidity and mortality rates, which
represent important outcomes after surgery, did not differ
significantly between the EN and ENIN groups (P > 0.05)
(Table 4).
A subgroup analysis of postoperative complications
found significantly lower rates of surgical site, pulmonary,
and urinary infections among ENIN patients (P < 0.05)
(Table 5). The two groups were similar in terms of the
occurrence of other morbid conditions (P = 0.642).
A major surgical complication was anastomotic
leakage, which occurred at a significantly lower rate in the
ENIN group than in the EN group (P = 0.018).

Table 2. Comparison of baseline demographic, nutritional, and surgical characteristics.
EN

ENIN

P

N

20

21

0.809

Age

62.6 ± 9.1

64.05 ± 9.04

0.645

Sex (M/F)

14/6

15/6

0.703

BMI (kg/m2)

21.1 ± 2.1

22 ± 1.98

0.572

Distal esophagus

6

4

0.455

Gastric

11

13

0.542

Pancreatic head

3

4

0.485

Distal esophagectomy

5

4

0.655

Total gastrectomy

11

13

0.437

Subtotal gastrectomy

6

4

0.399

Pancreaticoduodenectomy

3

4

0.485

Operative time (min)

205 ± 11.2

210 ± 10.7

0.424

Blood transfusions (patients/group)

15

16

0.782

Albumin (g/dL)

3.1 ± 0.52

3.2 ± 0.3

0.651

Prealbumin (mg/dL)

21.3 ± 1.1

22.1 ± 0.95

0.309

Transferrin (mg/dL)

205 ± 4.5

208 ± 38

0.286

Origin of malignancy

Surgical operations
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Table 3. Change in nutritional parameters of the study period.
Preop. day 1

Preop. day 7

Postop. day 7

P

Albumin

2.96 ± 0.3

2.99 ± 0.32

3 ± 0.33

0.433

Prealbumin

19.2 ± 0.4

20.1 ± 0.22

21.1 ± 0.20

0.254

Transferrin

192.5 ± 10.2

194.2 ± 11.1

195.5 ± 12.1

0.386

Albumin

2.95 ± 0.4

3.02 ± 0.25

3.05 ± 0.28

0.644

Prealbumin

20 ± 2.4

29.6 ± 2.03

28.1 ± 1.63

0.033

Transferrin

201 ± 15.1

214 ± 10.1

211 ± 8.9

0.125

EN

ENIN

Table 4. Rates of infectious complications, morbidity, mortality, and LHS.
EN

ENIN

P

Infectious complications

16 (31.3%)

6 (11.7%)

0.021

Overall morbidity

31 (60.8%)

20 (39.2%)

0.442

Mortality

2 (4.8%)

1 (2.4%)

0.216

LHS (days) (median)

18 (9–54)

12 (8–49)

0.032

EN

ENIN

P

16 (31.3%)

6 (11.7%)

0.021

Surgical site infection

5

2

0.013

Pulmonary infection

4

1

0.008

Urinary tract infection

3

1

0.020

Abdominal abscess

1

0

0.315

Sepsis

1

1

1

Venous catheter infection

2

1

0.253

15 (29.5%)

14 (27.5%)

0.642

Anastomotic leakage

3

1

0.018

Wound dehiscence

2

2

1

Renal failure

2

2

1

Respiratory failure

3

2

0.614

Bleeding

0

1

0.315

Pancreatic fistula

2

1

0.252

Delayed gastric emptying

2

3

0.614

2

2

1

Table 5. Detailed list of postoperative complications.

Infectious complications

Noninfectious complications

Circulatory failure
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4. Discussion
Nutrition is a fundamental component of human health.
In individuals with malnutrition or specific nutritional
deficiencies such as protein-energy malnutrition,
postsurgical recovery is generally more problematic
and poses significant health risks. Surgical procedures
represent a trauma for the organism, even in healthy
subjects, and cancer patients undergoing surgical
interventions are generally more vulnerable to lifethreatening complications, with predictably more
disappointing results.
Cancer patients frequently suffer from a number of
nutrition-related conditions such as malnutrition, cancer
cachexia, immune dysfunction, and inadequate wound
healing, which may have major effects on postoperative
morbidity and mortality (18,19). Thus, it is not surprising
to see that the role of nutritional support in patients
undergoing surgery has been extensively studied in
the last two decades. In this regard, Ef offers significant
advantages over Pn in this group of patients. As compared
to Pn, enteral formulations are less costly and have more
physiological impact. For instance, the maintenance of
gastrointestinal tract functionality in patients receiving
enteral nutrition helps prevent gut mucosal atrophy and
bacterial translocation (20–22), potentially diminishing
septic complications (23), which are among the most
dreaded postoperative complications. Recently, the
preferred route of administration of Ef involves the use
of nasoenteral tubes or feeding jejunostomy tubes. Pn
is generally reserved for patients who require complete
bowel rest due to conditions such as intestinal obstruction,
stercoral fistula, or an active episode of inflammatory
bowel disease (24). Its advantages include practical and
quick administration, rapid replacement of protein-energy
demand, and moderate to high patient compliance.
On the other hand, the established advantages of Ef
render it the nutritional route of choice in the perioperative
period. Accordingly, the American Society for Parenteral
and Enteral Nutrition (ASPEN) and the European Society
for Clinical Nutrition and Metabolism (ESPEN), the two
leading societies in the field of nutrition, endorse the use
of enteral nutrition, particularly during the perioperative
period (25,26).
Favorable effects of ImN, particularly in cancer
patients, partly arise from its effects on host defense
and protein synthesis, which ultimately result in the
modulation and increased levels of immune parameters
such as complements, immunoglobulins, interleukins,
lymphocytes, and natural killer cells (27–30).
These effects are associated with a reduction in the
rate of infections and LHS in patients undergoing radical
gastrointestinal surgery (13,14). In addition, the use of
ImN in elective gastrointestinal cancer surgery reduces

hospital costs through decreased rates of postoperative
complications and LHS (31). The beneficial effects of
nutritional support are more prominent when enteral
nutrition is used perioperatively.
Despite these beneficial effects, the effects of ImN on
mortality and overall complication rates have not been
demonstrated (15,32,33). Although ImN has beneficial
effects in major cancer surgery, it may also be associated
with certain detrimental effects, particularly in critically ill
patients (34–36).
The benefits of Ef and ImN in terms of hospital costs,
postoperative infectious complications, and patient
physiology have prompted us to use them in combination
and design this particular study.
In different studies performed, the duration of
nutritional support ranged between 3 and 14 days (37–39).
Some studies propose a minimum duration of 5 days for
ENIN preoperatively in gastrointestinal surgery patients
to observe a beneficial effect (33,40,41). Based on these
suggestions, perioperative nutritional support in the form
of ImN was administered for 7 days in our patients.
Abound is an immunonutritional product that
contains glutamine, arginine, and HMB. The beneficial
effects of these specific nutrients were previously described
in cancer cachexia and malnutrition, collagen synthesis,
wound healing in renal failure, hematological parameters
in malignancy, and in AIDS patients (42–45). The same
feeding combination has never been used in upper
gastrointestinal cancer surgery previously.
Patient selection is also an important consideration in
determining the appropriate nutritional support strategy.
In cancer patients, preoperative nutritional support
is generally required in the case of malnutrition and
malignant cachexia. It appears that some of the previous
studies did not fully take the issue of nutritional status into
consideration. Due to the absence of obvious favorable
effects of ImN in well-nourished patients (15,16,32), the
nutritional status of patients was initially evaluated and
nutritional support was only given to patients with cancerrelated moderate or severe malnutrition in our study.
In the present study, favorable effects of ENIN were
found on the postoperative infectious complication rate
and nutritional parameters. Surgical site, pulmonary, and
urinary tract infections occurred at a significantly lower
rate in patients fed with ENIN (P < 0.05), consistent with
previous reports (12,46,47).
Anastomotic leakage represents a serious postoperative
complication in gastrointestinal surgery and there was a
significantly lower incidence of anastomotic dehiscence in
our ENIM patients, similar to a recent report (48).
The nutritional status of the patients was assessed
using plasma albumin, prealbumin, and transferrin levels.
In both study groups, there was an increasing trend in
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all these laboratory parameters. However, only plasma
prealbumin levels showed a significant increase in the
ENIN group (P = 0.033). Previous similar studies reported
an improvement in certain nutritional parameters such as
serum prealbumin and/or transferrin levels (8,9).
LHS, morbidity, and mortality rates are other
important indicators in the efficiency assessment of ImN.
In this regard, despite a significant effect of ImN on LHS,
no change in mortality or overall complications could
be demonstrated in patients undergoing gastrointestinal
surgery (13,15,33). In our study, ENIN was associated with
a significant reduction in LHS (P = 0.032). This may be
due to the decrease in the rates of postoperative infection
and anastomotic leakage. On the other hand, neither
nutritional regimen had an effect on the overall morbidity
and mortality rates (P > 0.05)

In conclusion, a number of different beneficial effects of
ImN were observed in patients undergoing radical upper
gastrointestinal surgery in this prospective study. The
rate of postoperative infectious complications, LHS, and
serious morbidity such as anastomotic dehiscence were
significantly lower in patients fed ENIN perioperatively
than in those fed EN. Factors that determine the success
of this particular nutritional regimen include the timing
and duration of nutrition, the route of replacement, and
the severity of malnutrition. In this regard, a meticulous
preoperative assessment of nutritional status in cancer
patients is essential. In well-nourished cancer patients
and for short-term supplementation, this strategy may
be futile. However, preoperative enteral nutrition with
ImN for a minimum duration of 7 days may offer certain
advantages in terms of the outcome of cancer surgery
when the patient is malnourished.
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